Ocular Therapeutix (NSDQ:OCUL) reported fourth-quarter results that missed the consensus forecast. The Bedford, Mass.–based eye disease therapeutic developer posted losses of –$85.6 million, or –$1.21 per share, on sales of $7.3 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of –$26 million last year despite more than […]
MassDevice Earnings Roundup
Intersect ENT posts mixed bag Q4
Intersect ENT (NSDQ:XENT) posted a mixed bag of results for the fourth quarter, topping consensus revenue estimates but missing on earnings. The Menlo Park, Calif.-based company posted losses of –$20.2 million, or –62¢ per share, on sales of $28.2 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of […]
DarioHealth ticks up before market opens on Q4 results
DarioHealth (NSDQ:DRIO) shares ticked up in pre-market trading today on fourth-quarter revenues that equaled the consensus forecast. The New York–based digital therapeutics company posted losses of –$9 million for the three months ended Dec. 31, 2020, representing a more than doubled bottom-line slide from the same quarter last year on sales growth of 15.7%. The […]
Senseonics sinks on mixed bag Q4, massive bottom-line slide
Senseonics (NYSE:SENS) shares took a hit today on fourth-quarter losses that missed the consensus earnings forecast. SENS shares were hit hard at market close yesterday after financial results were released, dipping -15.7% to $2.69 per share. In pre-market trading this morning, they are down -7.8% at $2.48 per share. The Germantown, Md.-based implantable continuous glucose […]
Magenta Therapeutics rises on Street-beating Q4
Magenta Therapeutics (NSDQ:MGTA) shares ticked up today on fourth-quarter earnings that topped the consensus forecast. The Cambridge, Mass.-based stem cell transplantation technology developer posted losses of -$18.2 million, or -38¢ per share for the three months ended Dec. 31, 2020, marking a 21.8% bottom-line gain. Magenta’s earnings per share of -38¢ came in 3¢ ahead […]
Inovio Pharmaceuticals posts Street-beating Q4, touts HPV trial results
Inovio Pharmaceuticals (NSDQ:INO) shares dipped after hours today after the company presented its fourth-quarter earnings and touted clinical trial results. INO shares finished the day up 4.5% at $11.60 per share but have since dropped -2.2% after hours to $11.35 per share. The Plymouth Meeting, Pa.-based company posted losses of -$24.3 million, or -14¢ per […]
ICU Medical dips despite Street-beating Q4
ICU Medical (NSDQ:ICUI) shares took a slight hit today on fourth-quarter results that topped the consensus forecast. The San Clemente, Calif.-based infusion therapy and critical care technology developer posted profits of $26.1 million, or $1.21 per share, on sales of $320.5 million for the three months ended Dec. 31, 2020, for a 2.7% bottom-line gain on […]
Kala Pharmaceuticals slides on missed Q4 projections
Kala Pharmaceuticals (NSDQ:KALA) shares dipped this morning on fourth-quarter results that came up short of the consensus forecast. The Watertown, Mass.-based company posted losses of -$31.1 million, or -55¢ per share, on sales of $2.2 million for the three months ended Dec. 31, 2020, for a more than $10 million bottom-line slide on sales growth […]
Tandem Diabetes Care skyrockets after hours on Street-beating Q4
Tandem Diabetes Care (NSDQ:TNDM) shares soared after hours today on fourth-quarter results that topped the consensus forecast. Shares of TNDM were up 12.9% at $103.04 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.8%. The San Diego-based insulin delivery and […]
Insulet rises on Street-beating Q4 revenues
Insulet (NSDQ:PODD) shares rose before the market opened today on fourth-quarter results that beat the consensus revenue forecast. The Acton, Mass.-based wearable insulin delivery system developer posted losses of -$17.1 million, or -26¢ per share, on sales of $246.1 million for the three months ended Dec. 31, 2020, for a bottom-line slide into the red on […]
